No Data
No Data
Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations
Bio-Rad Laboratories | 10-K: Annual report
UBS Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Cuts Target Price to $355
Bio-Rad Laboratories Shares Fall on 4Q Sales Miss, Cost-Cutting Plans
UBS Adjusts Price Target on Bio-Rad Laboratories to $355 From $390, Keeps Buy Rating
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Cuts Target Price to $447
affable Blobfish_403 : The intense struggle between political power and market power in the election, the outcome is uncertain, today's debate is a major highlight.
章允量 :![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
104476495 : hi